Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sengeløv, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sengeløv, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1008-1009, 2003
© 2003 European Society for Medical Oncology

Original Paper

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of invasive bladder cancer

L. Sengeløv

Department of Oncology, Herlev University Hospital, Herlev, Denmark

The first 10% of the full text of this article appears below.


   Incidence
 

The crude incidence of bladder cancer in the European Union is 23 cases/100 000 per year, and the mortality is 10 cases/ 100 000 per year. Seventy per cent of patients with bladder cancer are >65 years of age.


   Diagnosis
 

Pathological diagnosis should . . . [Full Text of this Article]


   Staging and risk assessment
 

   Treatment of stage I disease
 

   Treatment of stage II and III disease
 

   Treatment of stage IV disease
 

   Response evaluation
 

   Follow-up
 

   Note
 

   Literature
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?